YouTubeFacebookLinkedInTwitterinstagramrss

Creative Biolabs’ Oncolytic Virus Construction Services Help to Shape the Future of Oncolytic Virotherapy



SHIRLEY, NY, UNITED STATES - Aug 18, 2020 - Oncolytic viruses (OVs), evolved and engineered for cancer specificity, are gaining momentum as a new drug class in the fight against cancer. Taking advantage of the OncoVirapy™ platform, Creative Biolabs is confident to provide first-rate customized oncolytic virus therapy development services for worldwide clients. Updated OV construction services are ready to accelerate related research covering a broad range of scope including Measles Virus, Adenovirus, Vaccinia Virus, Vescilar Stomatitis Virus, Herpes Simplex Virus, and Adeno-Associated Virus.

·Oncolytic Adenovirus Construction

As a non-enveloped virus containing a linear double-stranded DNA genome within an icosahedral capsid, adenoviruses (Ad) serotype 5 (Ad5) has been the most commonly used for experimental and clinical purposes among 57 human Ad serotypes.

When designing oncolytic adenovirus (OAd) vector for immune evasion and proper immune modulation for successful cancer immunotherapy, scientists at Creative Biolabs always have a variety of consideration, including high levels of pre-existing humoral immunity, and three major aspects of engineering, which are tumor selectivity, oncolytic efficacy and tumor infectivity.

·Oncolytic Herpes Simplex Virus Construction

Up to now, several oncolytic herpes simplex viruses (oHSVs) have been investigated in clinical trials. Creative Biolabs provides various armed oHSVs to achieve research and treatment purpose. Customized oHSV and proof-of-concept validation studies for OVs are also available at Creative Biolabs. With the increasing experience and knowledge of HSV system, coupled with the OncoVirapy™ platform, Creative Biolabs commits to developing efficacious oHSV and enabling wider applications in oncolytic virotherapy of cancers.

·Oncolytic Vaccinia Virus Construction

Vaccinia virus (VACV or VV) is a famous virus as the active constituent of the vaccine that eradicates smallpox, making it the first human disease to be eradicated. VV can be engineered as an oncolytic virus to attenuate the pathogenicity and increase tumor-specific replication through mutation of Thymidine Kinase (TK) and Vaccinia Growth Factor (VGF).

In Creative Biolabs, an experienced scientist team can manipulate and provide various armed oncolytic vaccinia virus for customers. By pathogenic and immunogenicity manipulation, the virus can specific replicated in the target tumor cells without severe immune reactions.

“The first virus used to treat cancer was studied in the 1900s, and now oncolytic virus has been extensively and deeply explored for over 100 years as a promising therapeutic,” said a senior scientist at Creative Biolabs, “with the established platform, we are familiar with oncolytic virus construction process for different kinds of species and able to provide specific virus to different types of tumors to facilitate your research.”

Detailed information can be found on https://www.creative-biolabs.com/oncolytic-virus.

About Creative Biolabs

Empowered by leading technology and years of experience in biomedical science, Creative Biolabs, to support novel therapeutics development, provides comprehensive, end-to-end services such as oncolytic virus engineering, construction, in vitro validation study, in vivo preclinical study, etc., as well as first-class products including oncolytic adenovirus construction kit and various kinds of pre-made oncolytic viruses.

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1